Ovascience, Inc. (OVAS): Hedge Funds Are Overweight This Biotech Stock

Page 1 of 5

Jennison Associates is on a shopping spree. Last week we reported a large biotech purchase by Jennison. Today we will report Jennison’s 600K share purchase of Ovascience Inc. (NASDAQ:OVAS). The stock was trading at $10 at the end of last year and lost nearly 50% of its value by February 3rd. Ovascience Inc. recouped all of its losses since then. Jennison Associates picked up 600K shares of OVAS during this roller coaster ride.

Hedge funds collectively usually own about 5% of an average stock’s outstanding shares. This number is closer to 20% with Ovascience Inc. Orbis Management had the largest stake (7.6%) in Ovascience at the end of 2015. Boston based Adage Capital also held a stake above 7%.

Follow Tempest Therapeutics Inc. (NASDAQ:TPST)

The details of Jennison’s filing can be seen below:

Ownership Summary Table

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
Jennison Associates 3,089,079 0 0 3,089,079 3,089,079 11.3%

Page 1 of 5 – SEC Filing

Securities and Exchange Commission

Washington, D.C. 20549

Schedule 13G

Under the Securities Exchange Act of 1934

(Amendment No. 3)*

March 31, 2016
(Date of event which requires filing of this statement)

Check the appropriate box to designate the rule pursuant to which

this schedule is filed:

(X) Rule 13d-1(b)

( ) Rule 13d-1(c)

( ) Rule 13d-1(d)

Name of Issuer: OvaScience, Inc.

Title of Class of Securities: Common Stock

CUSIP Number: 69014Q101

*The remainder of this cover page shall be filled out for a

reporting person’s initial filing on this form with respect to

the subject class of securities, and for any subsequent

amendment containing information which would alter the

disclosures provided in a prior cover page.

The information required in the remainder of this cover page

shall not be deemed to be “filed” for the purpose of Section 18

of the Securities Exchange Act of 1934 (“Act”) or otherwise

subject to the liabilities of that section of the Act but shall

be subject to all other provisions of the Act (however, see the


Follow Tempest Therapeutics Inc. (NASDAQ:TPST)

Page 1 of 5